Clinical Trial Update: Long-Term Open-Label Extension Study of Oral Levosimendan [Phase 3]

View source ↗

Summary

Tenax Therapeutics reports a long-term open-label extension study of oral levosimendan for pulmonary hypertension associated with HFpEF in Phase 3, with enrollm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension Associated with Hfpef

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Tenax Therapeutics, Inc. | Conditions: Pulmonary Hypertension Associated With HFpEF | Phase 3 | Status: ENROLLING_BY_INVITATION